LONDON, January 6, 2016 /PRNewswire/ --

Midatech closed its all-share acquisition of DARA BioSciences on 7 December (first announced in June), thereby acquiring a presence in the US oncology market via DARA's 20-strong sales force and portfolio of marketed cancer support products. On 18 December, Midatech announced the acquisition of anti-emetic drug, Zuplenz (from Galena, for $3.75m), a strong fit with DARA's existing anti-cancer support products. The new Midatech shares are listed as ADRs on NASDAQ on the back of its recent IPO in the US. Our valuation for Midatech, with our calculations now including DARA and Zuplenz, moves to $221.0m from $200.7m (or $13.29/ADR from $14.45/ADR due to greater share count).

(Photo: http://photos.prnewswire.com/prnh/20130417/608168 )

Our valuation for Midatech increases to $221.0m from $200.7m previously (or $13.29/ADR from $14.45/ADR), as we now incorporate the acquisitions of DARA and Zuplenz. Our valuation for DARA is based on forecast future operating cash flows (excluding potential payments on contingent value rights that are dependent on sales milestones, which exceed our relatively conservative projections). Additionally, we adjust our valuation for Midatech upward as our model has been rolled forward by six months and rebased to 2016. Click here [http://www.edisoninvestmentresearch.com/research/report/midatech4?utm_source=edison&utm_medium=pr_newswire&utm_campaign=midatech_06012016 ] to view the full report.

All reports published by Edison are available to download free of charge from its website http://www.edisoninvestmentresearch.com.

About Edison: We are an international equity advisory firm. We enable our client companies to achieve their capital market objectives. The team is made up of more than 80 analysts and investment professionals with many decades of experience. Our extensive company knowledge and industry expertise spans 10 business sectors and more than 700 listed companies globally. We give our corporate clients and investors privileged insight into global investment trends. Our distribution capability is key to ensuring a global investor audience can access our investment knowledge. Edison is authorised and regulated by the Financial Conduct Authority [https://register.fca.org.uk/ShPo_FirmDetailsPage?id=001b000000MfYL6AAN ]. Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

Contact details: Learn more at http://www.edisongroup.com and connect with Edison on:   


        
         
        LinkedIn http://www.linkedin.com/company/edison-investment-research  
        Twitter  http://www.twitter.com/Edison_Inv_Res  
        YouTube  http://www.youtube.com/edisonitv  
        Google+  https://plus.google.com/105425025202328783163/posts  

  


        
         
        For more information please contact: 
        Katherine Genis   
        Edison Investment Research 
        +1-646-653-7026

         
        Christian Glennie 
        Edison Investment Research 
        +44(0)20-3077-5727 
        healthcare@edisongroup.com 

  




    Photo: 
    http://photos.prnewswire.com/prnh/20130417/608168

SOURCE Edison Investment Research